- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05971771
Study to Assess Impact of Dietary Supplement on Sleep Health
July 24, 2023 updated by: Pharmanex
A Randomized, Double-Blind, Placebo Controlled, Single Center Pilot Study to Assess the Impact of Sleep Supplement on Sleep Health
Sleep is essential for health and wellness.
Sleep disruption can occur due to emotional stress, advancing age, hormonal imbalance, medications, and many other causes, some of which are presently unknown.
Most pharmaceutical sleep products artificially induce sedation without providing quality sleep.
Thus, a need exists for safe dietary supplement to promote and support healthy sleep that will encourage restful sleep.
This study will examine the efficacy, tolerance, and safety of sleep supplement as compared to a placebo.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zoe D Diana, MD
- Phone Number: 336-841-2040
- Email: zdraelos@northstate.net
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- The subject is male or female 20-60 years of age at the time of informed consent.
- Recorded baseline BMI is ≥18.5 and ≤29.9 kg/m2.
- A score of 5 or higher on the Pittsburgh Sleep Quality Index.
- Willing and able to give informed consent
- Willing to maintain consistent diet and physical activity through the study period.
- Willing to limit alcohol consumption to ≤14 drinks per week, no more than 4 drinks at a time, and no more than 1 drink within 4h of bedtime.
- Willing to limit caffeine consumption to no more than 4 servings per day and no caffeine within 6h of bedtime.
Exclusion Criteria:
- Could not or did not want to participate in clinical study.
- Taken nutritional supplements for sleep or stress in the previous 6 months.
- Have received non-pharmacological treatment for sleep disorders (eg. Cognitive behavioral therapy, relation therapy) in previous 6 months
- Any known allergy or intolerance to any of the ingredients contained in supplement.
- Planned surgical procedure during the course of the study.
- Used nicotine in the past 6 months.
- Have a major psychiatric disorder as determined by the Mini International Neuropsychiatric Inventory
- A history of unconventional sleep pattern, a diagnosed sleep disorder, or chronic medical condition that could affect energy/fatigue levels.
- Consume more than 400mg of caffeine per day in the past 2 weeks.
- Used any psychotropic medications, stimulants, cannabis, non-registered drug products, or illicit substances in the past 4 weeks.
- At risk of drug or alcohol abuse
- Used any sleep aids in the past 2 weeks.
- Employed in night shift work or rotational shift work
- Currently pregnant, nursing, planning to become pregnant, or unwilling to use a medically approved form of contraception will be excluded.
- Individuals who sleep more than 10 hours.
- Typically take a nap during the day.
- Those planning travel or vacation during the study period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Active: Sleep Supplement containing Magnesium and Saffron Extract
Powder that is to be mixed into 3oz. of water, 30-60 minutes before going to bed
|
14mg saffron extract and 250mg magnesium citrate that is powder that is mixed in 3-4 oz of water and consumed 30-60 minutes before going to bed
Other Names:
|
|
Placebo Comparator: Placebo
Placebo that is 2 softgels that will be taken with water, 30-60 minutes prior to going to bed.
|
Two softgels to be taken with water that is to be consumed approximately 30-60 minutes before going to bed
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline sleep quality index
Time Frame: Baseline, Day 1, Day 7, Day 28
|
Change from baseline in validated Pittsburgh Sleep Quality Index (0-21, higher number indicates poorer quality)
|
Baseline, Day 1, Day 7, Day 28
|
|
Change from baseline sleep duration and quality from diary
Time Frame: Baseline and Daily for 28 days
|
Change from baseline with Daily Sleep Diary
|
Baseline and Daily for 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline perceived stress scale
Time Frame: Baseline, Day 1, Day 7, Day 28
|
Change from baseline with validated perceived stress questionnaire
|
Baseline, Day 1, Day 7, Day 28
|
|
Change from baseline Insomnia severity index
Time Frame: Baseline, Day 1, Day 7, Day 28
|
Change from baseline using validated Insomnia Severity Index (0-28, higher number indicates more severe insomnia)
|
Baseline, Day 1, Day 7, Day 28
|
|
Change from baseline in restorative sleep as measured by Restorative Sleep Questionnaire (RSQ)
Time Frame: Baseline, Day 1, Day 7, Day 28
|
Change from baseline using restorative sleep questionnaire as measured by Restorative Sleep Questionnaire (RSQ) that is a 9-item scale/question assessing symptoms over the last week.
The total score ranges from 0 to 100, with higher scores indicating better restorative sleep
|
Baseline, Day 1, Day 7, Day 28
|
|
Change from baseline in mood
Time Frame: Baseline, Day 1, Day 7, Day 28
|
Change from baseline using abbreviated Profile of Mood States (POMS) is a widely used questionnaire of 24 items and four scales.
Total numbers range from 0-not at all to 4-very strong
|
Baseline, Day 1, Day 7, Day 28
|
|
Change from baseline in skin attributes
Time Frame: Baseline, Day 7, and Day 28
|
Change from baseline in skin attributes using 1-5 scale (1 strongly disagree to 5 strongly agree) with questionnaire regarding skin appearance (youthfulness, glow, evenness, hydration, etc)
|
Baseline, Day 7, and Day 28
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in diastolic blood pressure measurement (safety measure)
Time Frame: Baseline and Day 28
|
Change from baseline diastolic blood pressure changes using sphygmomanometer
|
Baseline and Day 28
|
|
Change in systolic blood pressure measurement (safety measure)
Time Frame: Baseline and Day 28
|
Change from baseline systolic blood pressure changes using sphygmomanometer
|
Baseline and Day 28
|
|
Change in body weight
Time Frame: Baseline and Day Day 28
|
change from baseline in body weight as measured in pounds
|
Baseline and Day Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
August 1, 2023
Primary Completion (Estimated)
August 30, 2023
Study Completion (Estimated)
December 31, 2023
Study Registration Dates
First Submitted
June 15, 2023
First Submitted That Met QC Criteria
July 24, 2023
First Posted (Actual)
August 2, 2023
Study Record Updates
Last Update Posted (Actual)
August 2, 2023
Last Update Submitted That Met QC Criteria
July 24, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- DCS-7-23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep
-
University of Wisconsin, MadisonPhilips HealthcareCompletedSleep, Slow-wave Sleep, Sleep Enhancement, Sleep Optimization
-
Brain Electrophysiology Laboratory CompanyRecruiting
-
University GhentEuropean CommissionCompleted
-
Mahidol UniversityRamathibodi HospitalNot yet recruitingSleep Inertia | Sleep, Slow-wave Sleep, Sleep Enhancement, Sleep Optimization | Night Shift WorkThailand
-
Northumbria UniversityCompletedSleep | Mood | Poor Quality Sleep | Good Sleep HabitUnited Kingdom
-
Universidade Federal de PernambucoEnrolling by invitationSleep | Obstructive Sleep Apnea (OSA)Brazil
-
Atlas UniversityCompletedSleep | Surgery | Sleep QualityTurkey (Türkiye)
-
Mersin UniversityCompletedSleep Quality | Sleep PerceptionTurkey (Türkiye)
-
Brigham and Women's HospitalNot yet recruitingObstructive Sleep Apnea | Sleep-disordered BreathingUnited States
-
Institute of Nutrition, Slovenia (Nutris)Valens Int. d.o.o., Slovenija; Faculty of Pharmacy, University of Ljubljana... and other collaboratorsNot yet recruitingSleep Quality | Sleep Onset LatencySlovenia
Clinical Trials on Treatment
-
PfizerCompleted
-
PfizerCompleted
-
Chiesi Farmaceutici S.p.A.Completed
-
Gilead SciencesCompletedChronic Lymphocytic LeukemiaUnited States
-
JW PharmaceuticalCompletedHealthyKorea, Republic of
-
PfizerCompleted
-
AstraZenecaParexelCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingIntra-articular Fracture of the Mandibular CondyleFrance
-
New Mexico VA Healthcare SystemCompletedPost Traumatic Stress DisorderUnited States
-
PfizerCompletedHealthy VolunteersUnited States